{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "GMP cyclique : Questions médicales les plus fréquentes",
"headline": "GMP cyclique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les GMP cyclique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-08",
"dateModified": "2025-04-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "GMP cyclique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Nucléotides guanyliques",
"url": "https://questionsmedicales.fr/mesh/D006150",
"about": {
"@type": "MedicalCondition",
"name": "Nucléotides guanyliques",
"code": {
"@type": "MedicalCode",
"code": "D006150",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.426"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Dibutyryl GMP cyclique",
"alternateName": "Dibutyryl Cyclic GMP",
"url": "https://questionsmedicales.fr/mesh/D003995",
"about": {
"@type": "MedicalCondition",
"name": "Dibutyryl GMP cyclique",
"code": {
"@type": "MedicalCode",
"code": "D003995",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.426.160.325"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "GMP cyclique",
"alternateName": "Cyclic GMP",
"code": {
"@type": "MedicalCode",
"code": "D006152",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ute Römling",
"url": "https://questionsmedicales.fr/author/Ute%20R%C3%B6mling",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Fengyang Li",
"url": "https://questionsmedicales.fr/author/Fengyang%20Li",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Zhijian J Chen",
"url": "https://questionsmedicales.fr/author/Zhijian%20J%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Biology , Howard Hughes Medical Institute , Department of Immunology , and Animal Resource Center , University of Texas Southwestern Medical Center , Dallas 75390-9148 , Texas , United States."
}
},
{
"@type": "Person",
"name": "Roshni R Kharadi",
"url": "https://questionsmedicales.fr/author/Roshni%20R%20Kharadi",
"affiliation": {
"@type": "Organization",
"name": "Department of Plant, Soil and Microbial Sciences, Michigan State University, East Lansing, MI, United States."
}
},
{
"@type": "Person",
"name": "George W Sundin",
"url": "https://questionsmedicales.fr/author/George%20W%20Sundin",
"affiliation": {
"@type": "Organization",
"name": "Department of Plant, Soil and Microbial Sciences, Michigan State University, East Lansing, MI, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Quantification of cyclic AMP and cyclic GMP levels in Krebs-Henseleit solution by LC-MS/MS: Application in washed platelet aggregation samples.",
"datePublished": "2022-09-27",
"url": "https://questionsmedicales.fr/article/36215878",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jchromb.2022.123472"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease.",
"datePublished": "2023-01-20",
"url": "https://questionsmedicales.fr/article/36682595",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.vph.2023.107143"
}
},
{
"@type": "ScholarlyArticle",
"name": "Application of microfluidic chip technology to study the inhibitory effect of tetramethylpyrazine on platelet aggregation, activation, and phosphatidylserine exposure mediated by pathological high shear rate.",
"datePublished": "2022-11-10",
"url": "https://questionsmedicales.fr/article/36367784",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MBC.0000000000001179"
}
},
{
"@type": "ScholarlyArticle",
"name": "In-vivo platelet activation and aggregation during and after acute atherothrombotic myocardial infarction in patients with and without Type-2 diabetes mellitus treated with ticagrelor.",
"datePublished": "2022-05-25",
"url": "https://questionsmedicales.fr/article/35623547",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.vph.2022.107000"
}
},
{
"@type": "ScholarlyArticle",
"name": "Downscaling platelet cryopreservation: Are platelets frozen in tubes comparable to standard cryopreserved platelets?",
"datePublished": "2024-01-17",
"url": "https://questionsmedicales.fr/article/38230448",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/trf.17724"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides nucléiques, nucléotides et nucléosides",
"item": "https://questionsmedicales.fr/mesh/D009706"
},
{
"@type": "ListItem",
"position": 3,
"name": "Nucléotides",
"item": "https://questionsmedicales.fr/mesh/D009711"
},
{
"@type": "ListItem",
"position": 4,
"name": "Ribonucléotides",
"item": "https://questionsmedicales.fr/mesh/D012265"
},
{
"@type": "ListItem",
"position": 5,
"name": "Nucléotides guanyliques",
"item": "https://questionsmedicales.fr/mesh/D006150"
},
{
"@type": "ListItem",
"position": 6,
"name": "GMP cyclique",
"item": "https://questionsmedicales.fr/mesh/D006152"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : GMP cyclique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur GMP cyclique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur GMP cyclique",
"description": "Comment mesurer le GMP cyclique dans le corps ?\nQuels tests diagnostiques sont utilisés pour le GMPc ?\nLe GMPc est-il impliqué dans des maladies spécifiques ?\nQuels biomarqueurs sont liés au GMPc ?\nComment le GMPc est-il lié à la fonction cardiaque ?",
"url": "https://questionsmedicales.fr/mesh/D006152?mesh_terms=Platelet+Aggregation&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur GMP cyclique",
"description": "Quels symptômes sont associés à des niveaux bas de GMPc ?\nDes niveaux élevés de GMPc provoquent-ils des symptômes ?\nLe GMPc affecte-t-il la pression artérielle ?\nQuels symptômes neurologiques sont liés au GMPc ?\nLe GMPc influence-t-il la fonction rénale ?",
"url": "https://questionsmedicales.fr/mesh/D006152?mesh_terms=Platelet+Aggregation&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur GMP cyclique",
"description": "Comment maintenir des niveaux sains de GMPc ?\nLe stress affecte-t-il le GMPc ?\nY a-t-il des habitudes à éviter pour le GMPc ?\nL'exercice physique influence-t-il le GMPc ?\nLes suppléments peuvent-ils affecter le GMPc ?",
"url": "https://questionsmedicales.fr/mesh/D006152?mesh_terms=Platelet+Aggregation&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur GMP cyclique",
"description": "Quels médicaments augmentent le GMPc ?\nComment le GMPc est-il ciblé dans le traitement des maladies ?\nLe GMPc a-t-il un rôle dans la thérapie génique ?\nQuels effets secondaires sont liés aux traitements du GMPc ?\nLe GMPc est-il impliqué dans des traitements expérimentaux ?",
"url": "https://questionsmedicales.fr/mesh/D006152?mesh_terms=Platelet+Aggregation&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur GMP cyclique",
"description": "Quelles complications sont liées à des niveaux anormaux de GMPc ?\nLe GMPc est-il impliqué dans des maladies chroniques ?\nDes niveaux élevés de GMPc peuvent-ils causer des problèmes ?\nLe GMPc est-il lié à des troubles métaboliques ?\nComment le GMPc affecte-t-il la santé mentale ?",
"url": "https://questionsmedicales.fr/mesh/D006152?mesh_terms=Platelet+Aggregation&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur GMP cyclique",
"description": "Quels facteurs augmentent le risque d'anomalies de GMPc ?\nL'alimentation influence-t-elle le GMPc ?\nLe vieillissement affecte-t-il le GMPc ?\nLe manque d'exercice influence-t-il le GMPc ?\nLes maladies héréditaires affectent-elles le GMPc ?",
"url": "https://questionsmedicales.fr/mesh/D006152?mesh_terms=Platelet+Aggregation&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer le GMP cyclique dans le corps ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le GMPc peut être mesuré par des tests biochimiques dans des échantillons de sang ou de tissus."
}
},
{
"@type": "Question",
"name": "Quels tests diagnostiques sont utilisés pour le GMPc ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'immunoessai et des dosages enzymatiques sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Le GMPc est-il impliqué dans des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux de GMPc sont associés à des maladies cardiovasculaires et neurologiques."
}
},
{
"@type": "Question",
"name": "Quels biomarqueurs sont liés au GMPc ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le GMPc est souvent mesuré en relation avec d'autres biomarqueurs comme le NO et les prostaglandines."
}
},
{
"@type": "Question",
"name": "Comment le GMPc est-il lié à la fonction cardiaque ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le GMPc régule la relaxation des muscles cardiaques, influençant la fonction cardiaque globale."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à des niveaux bas de GMPc ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux bas peuvent entraîner des problèmes de vasodilatation et des troubles circulatoires."
}
},
{
"@type": "Question",
"name": "Des niveaux élevés de GMPc provoquent-ils des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés peuvent causer des maux de tête et des troubles de la vision."
}
},
{
"@type": "Question",
"name": "Le GMPc affecte-t-il la pression artérielle ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le GMPc joue un rôle dans la régulation de la pression artérielle par la vasodilatation."
}
},
{
"@type": "Question",
"name": "Quels symptômes neurologiques sont liés au GMPc ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies de GMPc peuvent être associées à des troubles neurologiques comme l'anxiété."
}
},
{
"@type": "Question",
"name": "Le GMPc influence-t-il la fonction rénale ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le GMPc est impliqué dans la régulation de la fonction rénale et de la filtration glomérulaire."
}
},
{
"@type": "Question",
"name": "Comment maintenir des niveaux sains de GMPc ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et l'hydratation peuvent aider à maintenir des niveaux sains."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il le GMPc ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut réduire les niveaux de GMPc, affectant la santé cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter pour le GMPc ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et une consommation excessive d'alcool peut aider à maintenir des niveaux de GMPc."
}
},
{
"@type": "Question",
"name": "L'exercice physique influence-t-il le GMPc ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut augmenter les niveaux de GMPc et améliorer la santé cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Les suppléments peuvent-ils affecter le GMPc ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains suppléments, comme les acides gras oméga-3, peuvent influencer positivement les niveaux de GMPc."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le GMPc ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de la phosphodiestérase, comme le sildénafil, augmentent les niveaux de GMPc."
}
},
{
"@type": "Question",
"name": "Comment le GMPc est-il ciblé dans le traitement des maladies ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le GMPc est ciblé pour traiter des maladies cardiovasculaires et pulmonaires par des vasodilatateurs."
}
},
{
"@type": "Question",
"name": "Le GMPc a-t-il un rôle dans la thérapie génique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des approches de thérapie génique visent à moduler les niveaux de GMPc pour traiter certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires sont liés aux traitements du GMPc ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des maux de tête, des rougeurs et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "Le GMPc est-il impliqué dans des traitements expérimentaux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des recherches explorent l'utilisation de GMPc dans des traitements pour des cancers et des maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à des niveaux anormaux de GMPc ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux peuvent entraîner des complications cardiovasculaires et neurologiques graves."
}
},
{
"@type": "Question",
"name": "Le GMPc est-il impliqué dans des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déséquilibres de GMPc sont associés à des maladies chroniques comme l'hypertension."
}
},
{
"@type": "Question",
"name": "Des niveaux élevés de GMPc peuvent-ils causer des problèmes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés peuvent être liés à des troubles de la vision et des migraines."
}
},
{
"@type": "Question",
"name": "Le GMPc est-il lié à des troubles métaboliques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies de GMPc peuvent contribuer à des troubles métaboliques comme le diabète."
}
},
{
"@type": "Question",
"name": "Comment le GMPc affecte-t-il la santé mentale ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des déséquilibres de GMPc sont associés à des troubles de l'humeur et à l'anxiété."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'anomalies de GMPc ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, l'obésité et le stress chronique augmentent le risque d'anomalies de GMPc."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le GMPc ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en graisses saturées peut nuire aux niveaux de GMPc."
}
},
{
"@type": "Question",
"name": "Le vieillissement affecte-t-il le GMPc ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut entraîner une diminution des niveaux de GMPc, affectant la santé globale."
}
},
{
"@type": "Question",
"name": "Le manque d'exercice influence-t-il le GMPc ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire peut réduire les niveaux de GMPc et augmenter les risques cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les maladies héréditaires affectent-elles le GMPc ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques peuvent perturber la signalisation du GMPc, augmentant les risques de complications."
}
}
]
}
]
}
Cyclic Nucleotides are important in regulating platelet function. Increases in 3'5'-cyclic adenosine monophosphate (cAMP) and 3'5'-cyclic guanosine monophosphate (cGMP) inhibit platelet aggregation an...
No study has compared pharmacologic properties of ticagrelor and clopidogrel in non-dialysis patients with stage 4-5 chronic kidney disease (CKD)....
We conducted a double-blind RCT to compare effects of ticagrelor and clopidogrel in 48 CKD, with the primary outcome of ADP-induced platelet aggregation (WBPA) after 2 weeks of DAPT. In a parallel arm...
Average age of CKD was 53.7 years, with 62% women, 54% African American, and 42% with stage 5 CKD. Ticagrelor generated statistically lower WBPA values post treatment [median 0 Ω (IQR 0, 2)] vs. clopi...
We report significant differences in platelet aggregation and anti-inflammatory properties between ticagrelor- and clopidogrel-based DAPT in non-dialysis people with stage 4-5 CKD. These notable infla...
In order to study the antithrombotic effect and mechanism of tetramethylpyrazine (TMA)....
In this study, we developed a microfluidic chip model that can mimic normal arteries and stenotic arterial vessels, and studied the inhibitory effects of TMA on platelet aggregation, activation (P-sel...
The results showed that TMA significantly inhibited the platelet aggregation, activation and PS exposure induced by pathological high shear rate. Under static conditions, TMA can inhibit ADP and risto...
The results indicated that TMA mainly inhibited platelet aggregation, activation and PS exposure by inhibiting the binding of von Willebrand factor (vWF) to the GPIb/IX/V complex, and partially inhibi...
Patients with type-2 diabetes are twice as likely to suffer from acute myocardial infarction (AMI) and have a higher incidence of recurrent events than their non-diabetic counterparts. Ticagrelor is a...
P...
Ninety-seven patients were prospectively enrolled (diabetes, N = 33; no diabetes, N = 64). No difference was observed in the expression of P-selectin and PAC-1 at any given point between diabetes and ...
Ticagrelor demonstrated similar in-vivo effects on platelet activation and aggregation regardless of diabetes status in patients presenting with AMI....
Platelet cryopreservation extends the shelf-life to at least 2 years. However, platelets are altered during the freeze/thaw process. Downscaling platelet cryopreservation by freezing in tubes would en...
Platelets were prepared for cryopreservation using 5%-6% DMSO and processed using standard protocols or aliquoted into 2 mL tubes. Platelets were hyperconcentrated to 25 mL (standard CPPs) or 200 μL (...
The use of different insulators for tubes changed the freezing rate of platelets compared to platelets frozen using the standard protocol (p < .001). However, this had no impact on the recovery of the...
Freezing platelets in tubes modified the freezing rate and altered some platelet characteristics. However, the functional characteristics remained comparable, demonstrating the feasibility of downscal...
The activation of platelets and proliferation of vascular smooth muscle cells (VSMCs) in the vascular intima play an essential role in the pathological mechanism of vascular restenosis (RS). Rosmarini...
Platelet function during inflammation is dependent on activation by endogenous nucleotides. Non-canonical signalling via the P2Y...
Platelets obtained from healthy human volunteers were incubated with ADP, Ap3A, NAD...
Platelet aggregation and binding to fibrinogen induced by ADP was not mimicked by NAD...
Platelet function (aggregation vs motility) can be differentially modulated by biased-agonist activation of P2Y...
This article is part of a themed issue on Platelet purinergic receptor and non-thrombotic disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181....
Especially in disease conditions, platelets can encounter activating agents in circulation....
To investigate the extent to which previously activated platelets can be reactivated and whether in-and reactivation applies to different aspects of platelet activation and thrombus formation....
Short-and long-term effects of glycoprotein VI (GPVI) and G protein-coupled receptor (GPCR) stimulation on platelet activation and aggregation potential were compared via flow cytometry and plate-base...
After 30 minutes of stimulation with thrombin receptor activator peptide 6 (TRAP6) or adenosine diphosphate (ADP), platelets secondarily decreased in PAC-1 binding and were less able to aggregate. The...
This work emphasizes that prior platelet activation can be reversed, whereafter platelets can be reactivated through a different receptor. Reversed, previously activated platelets can contribute to th...
Acute leukemia (AL) is a hematological malignancy with high morbidity and mortality that is caused by abnormal hematopoietic stem cells. AL can change the parameters, quality, and function of platelet...
Platelets are necessary for maintaining haemostasis. Separately, platelets are important for the propagation of inflammation during the host immune response against infection. The activation of platel...